Rao Madhavi, Mikdashi Jamal
Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, USA.
Open Access Rheumatol. 2023 Jul 27;15:125-137. doi: 10.2147/OARRR.S295036. eCollection 2023.
Infections remain one of the leading causes of death in systemic lupus erythematosus (SLE), despite awareness of factors contributing to increased susceptibility to infectious diseases in SLE. Clinicians report challenges and barriers when encountering infection in SLE as certain infections may mimic a lupus flare. There are no evidence-based practice guidelines in the management of fever in SLE, with suboptimal implementations of evidence-based benefits related to infectious disease control and/or prevention strategies in SLE. Vigilance in identifying an opportunistic infection must be stressed when confronted by a diagnostic challenge during a presentation with a febrile illness in SLE. A balanced approach must focus on management of infections in SLE, and reduction in the glucocorticoids dose, given the need to control lupus disease activity to avoid lupus related organ damage and mortality. Clinical judgement and application of biomarkers of lupus flares could reduce false positives and overdiagnosis and improve differentiation of infections from lupus flares. Further precision-based risk and screening measures must identify individuals who would benefit most from low dose immunosuppressive therapy, targeted immune therapy, and vaccination programs.
尽管人们已经认识到系统性红斑狼疮(SLE)患者易患传染病的相关因素,但感染仍是SLE患者的主要死因之一。临床医生报告称,在SLE患者发生感染时会遇到挑战和障碍,因为某些感染可能会模仿狼疮发作。在SLE患者发热管理方面,尚无基于证据的实践指南,在SLE患者中,与传染病控制和/或预防策略相关的循证获益实施效果欠佳。当SLE患者出现发热性疾病且面临诊断挑战时,必须强调警惕机会性感染。鉴于需要控制狼疮疾病活动以避免狼疮相关器官损害和死亡,一种平衡的方法必须侧重于SLE患者感染的管理以及糖皮质激素剂量的减少。狼疮发作生物标志物的临床判断和应用可以减少假阳性和过度诊断,并改善感染与狼疮发作的鉴别。进一步基于精准的风险和筛查措施必须识别出那些将从低剂量免疫抑制治疗、靶向免疫治疗和疫苗接种计划中获益最大的个体。